For a country that had grappled with drug shortages for too long, the availability of low-cost generics has considerably improved access to medicines. Government health policy has been a key driver of this development. As part of wide-ranging reforms, the government instituted new drug registration measures aimed at curbing illegal imports, while at the same time promoting importation of legitimate generic products.
New analysis from Frost & Sullivan (medicaldevices.frost.com), Healthcare Overview of Mozambique, finds that the market earned revenues of $49.4 million in 2009 and estimates this to reach $110.5 million in 2016. The following segments are covered in the research: branded and generic drugs.
"The pharmaceutical market in Mozambique will be driven by the increased availability of affordable generic drugs, " notes Frost & Sullivan Healthcare Research Analyst Ishe Zingoni. "The rising incidences of infectious diseases in the country coupled with economic growth, and thus rising incomes, will drive spending, boosting market prospects."
Greater availability of affordable drugs drives the uptake of medication. Supply of generic drugs has improved since the government revamped the regulatory environment and enforced mechanisms to eliminate counterfeits. Additionally, the market has taken off with new regulations in place that make it mandatory for doctors to prescribe generic drugs wherever possible.
However, one of the most significant challenges in Mozambique is the lack of adequate distribution networks. This has affected the drug supply, and contributed to shortages in some cases.
"Outside of Maputo, distribution networks and storage facilities are insufficient, " explains Zingoni. "It is, therefore, a challenge to move commercial goods to other parts of the country, mainly the central and northern provinces. The result is that citizens of remote regions lack access to medicines that are otherwise available in the country."
The rural market, which has not been exploited to its full potential, represents vast opportunities for pharmaceutical companies. Distribution networks in remote areas are however still under-developed and so companies will have to utilise the informal sector.
"Pharmaceutical companies need to leverage the informal network in order to penetrate the rural market, " advises Zingoni. "This approach suits over-the-counter (OTC) products whose uptake has not been curtailed by the country's shortage of qualified healthcare workers."
Healthcare Overview of Mozambique is part of the Medical Devices Growth Partnership Services programme, which also includes research in the following markets:: Strategic Analysis of Medical Imaging Devices in Kenya, Strategic Analysis of Healthcare Industry in Zimbabwe, Strategic Analysis of the Healthcare Industry in Kenya, Strategic Analysis of the Healthcare Industry in Tanzania and The Medical Insurance Markets in sub-Sahara Africa. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
If you are interested in more information about this study, please send an E: to Christie Cronje, Corporate Communications, at christie.cronje[.]frost.com, with your full name, company name, title, telephone number, company E: address, company website, city, state and country.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit frost.com.
Healthcare Overview of Mozambique / M519